
Scan beyond Intellia Therapeutics and line up other rare-disease and biotech prospects with resilient balance sheets using our hand-picked list of solid balance sheet and fundamentals (24 results) for comparison.
To own Intellia Therapeutics, you need to believe that one-time CRISPR editing for HAE and ATTR can move from trials into repeatable commercial delivery, even while the firm is still loss making. The analyst consensus narrative on Simply Wall St leans on future revenue and earnings expansion, yet the latest quarterly loss of US$127.49 million underlines how dependent the story is on access to capital and careful spend.
In the near term, lonvo z approval timing and launch execution look like the key swing factors. Phase 3 nex z outcomes sit close behind. The bigger risk right now is that any safety or regulatory issue for either asset, or payer pushback on high upfront pricing, slows uptake and stretches the cash runway. The recent results do not appear to change that risk reward balance in a major way.
The most relevant fresh data point is MAGNITUDE 2 enrollment completion for nex z in ATTRv PN. That trial now moves fully into the follow up and readout phase, which tightens the link between Intellia Therapeutics' day-to-day spending and the timing of a second potential commercial asset behind lonvo z. With around 60 patients, the design is relatively lean, so each data point matters for confidence in liver-directed CRISPR and long-term safety.
For you as an investor, that update adds another upcoming catalyst beside lonvo z's FDA decision, without changing the core risk profile outlined earlier. The business is still reporting sizeable net losses over the first nine months of 2026 at US$330.35 million, so progress on nex z is less about near term revenue and more about whether Intellia Therapeutics can build a multi-product rare disease franchise that justifies continuing high R&D and potential future financing.
Intellia Therapeutics' narrative projects US$645.2 million revenue and US$118.1 million earnings by 2029, which analysts frame as requiring very large annual revenue growth of 121.3% and an earnings improvement of about US$518.1 million from the current loss of US$400.0 million.
Uncover why Intellia Therapeutics' fair value indicates a 138% potential upside to its current price, a gap that could narrow quickly as sentiment catches up.
One catalyst that bearish analysts focus on is the risk that Intellia Therapeutics keeps spending heavily while product uptake lags. Before this news, the lowest forecasts were only about US$18.6 million of revenue and US$3.3 million of earnings by 2029. That is far more cautious than consensus; treat this as one viewpoint and explore several others before deciding what feels reasonable to you.
Explore 3 other Intellia Therapeutics fair value estimates, including one that suggests it could be worth just $22.78!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider conducting your own research and forming an independent view.
Once you have a view on Intellia Therapeutics, it can help to benchmark that opinion against other companies with different risk and return profiles. The Simply Wall St Screener lets you scan across sectors and market caps so you can build a watchlist that fits your goals instead of relying on a single high conviction idea.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com